# Veracyte Inc. (VCYT)

Source: https://www.quantisnow.com/company/VCYT
Generated: 2026-11-14T04:53:21.618Z

- Ticker: VCYT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical Specialities
- IPO year: 2013
- SEC CIK: 0001384101
- Website: veracyte.com

## About

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

## Latest VCYT news and filings

- 2026-11-12 12:00 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-veracyte-inc-6786035)
- 2026-11-05 18:27 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-veracyte-inc-6775653)
- 2026-11-05 13:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Veracyte Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-veracyte-inc-6774924)
- 2026-11-05 11:32 UTC [Analyst Downgrade] [Veracyte downgraded by Leerink Partners with a new price target](https://www.quantisnow.com/insight/veracyte-downgraded-by-leerink-partners-with-a-new-price-target-6774227)
- 2026-11-04 21:08 UTC [SEC Form 8-K] [Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/veracyte-inc-filed-sec-form-8-k-results-of-operations-and-6772543)
- 2026-11-04 21:05 UTC [Earnings] [Veracyte Announces Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/veracyte-announces-third-quarter-2026-financial-results-6772294)
- 2026-11-02 14:00 UTC [Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026](https://www.quantisnow.com/insight/ten-afirma-abstracts-to-highlight-thyroid-nodule-diagnosis-and-cancer-6766417)
- 2026-10-29 20:50 UTC [SEC Form 4] [SEC Form 4 filed by Veracyte Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-veracyte-inc-6763958)
- 2026-10-29 20:05 UTC [Conference Announcement] [Veracyte to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/veracyte-to-participate-in-upcoming-investor-conferences-6763385)
- 2026-10-28 20:05 UTC [SEC Form 4] [Director Eastham Karin sold $742,573 worth of shares (14,850 units at $50.00) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-eastham-karin-sold-742573-worth-of-shares-14850-units-6761281)
- 2026-10-28 20:05 UTC [SEC Form 4] [Director Holstein Jens sold $727,500 worth of shares (15,000 units at $48.50) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-holstein-jens-sold-727500-worth-of-shares-15000-units-6761276)
- 2026-10-27 20:30 UTC [SEC Form 144] [SEC Form 144 filed by Veracyte Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-veracyte-inc-6759510)
- 2026-10-23 08:00 UTC [Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer](https://www.quantisnow.com/insight/phase-iii-trial-shows-veracytes-decipher-prostate-test-can-predict-6755662)
- 2026-10-20 20:10 UTC [SEC Form 4] [Director Bhanji Muna sold $81,457 worth of shares (1,864 units at $43.70) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-bhanji-muna-sold-81457-worth-of-shares-1864-units-6752168)
- 2026-10-19 12:00 UTC [Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026](https://www.quantisnow.com/insight/six-studies-to-highlight-veracytes-genomic-tests-across-breast-prostate-6750265)
- 2026-10-16 13:15 UTC [Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test](https://www.quantisnow.com/insight/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-6748846)
- 2026-10-14 20:05 UTC [Earnings Date] [Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026](https://www.quantisnow.com/insight/veracyte-to-release-third-quarter-2026-financial-results-on-november-6746503)
- 2026-09-29 12:00 UTC [Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation](https://www.quantisnow.com/insight/phase-iii-trial-demonstrates-veracytes-decipher-prostate-test-predicts-benefit-6728416)
- 2026-09-25 21:12 UTC [Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026](https://www.quantisnow.com/insight/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-6726724)
- 2026-09-22 21:16 UTC [SEC Form 4] [Global Chief Commercial Off Leite John sold $160,600 worth of shares (4,015 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 124,329 units (SEC Form 4)](https://www.quantisnow.com/insight/global-chief-commercial-off-leite-john-sold-160600-worth-of-6723276)
- 2026-09-16 20:08 UTC [SEC Form 4] [Director Holstein Jens sold $204,747 worth of shares (5,000 units at $40.95) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 27,471 units (SEC Form 4)](https://www.quantisnow.com/insight/director-holstein-jens-sold-204747-worth-of-shares-5000-units-6717512)
- 2026-09-14 20:07 UTC [SEC Form 8-K] [Veracyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/veracyte-inc-filed-sec-form-8-k-entry-into-a-material-6714451)
- 2026-09-14 20:05 UTC [Mergers & Acquisitions] [Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform](https://www.quantisnow.com/insight/veracyte-acquires-convergent-genomics-expanding-its-urology-diagnostics-portfolio-with-6714379)
- 2026-09-04 23:54 UTC [SEC Form 4] [Chief Financial Officer Chambers Rebecca sold $157,394 worth of shares (3,652 units at $43.10) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,603 shares, decreasing direct ownership by 4% to 166,025 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-financial-officer-chambers-rebecca-sold-157394-worth-of-shares-6707112)
- 2026-09-04 23:54 UTC [SEC Form 4] [VP, Chief Accounting Officer Wygant Jonathan covered exercise/tax liability with 1,361 shares, decreasing direct ownership by 3% to 43,226 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/vp-chief-accounting-officer-wygant-jonathan-covered-exercisetax-liability-with-6707111)
- 2026-09-04 23:54 UTC [SEC Form 4] [EVP, General Counsel Mcguire Annie sold $140,212 worth of shares (3,254 units at $43.09) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,215 shares, decreasing direct ownership by 5% to 131,160 units (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/evp-general-counsel-mcguire-annie-sold-140212-worth-of-shares-6707110)
- 2026-09-04 23:53 UTC [SEC Form 4] [Chief Executive Officer Stapley Marc covered exercise/tax liability with 8,782 shares, decreasing direct ownership by 2% to 432,073 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-executive-officer-stapley-marc-covered-exercisetax-liability-with-8782-6707109)
- 2026-09-04 23:54 UTC [SEC Form 4] [Chief Scientific & Med Officer Febbo Phillip G. covered exercise/tax liability with 3,639 shares and sold $564,410 worth of shares (13,110 units at $43.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 133,048 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-scientific-med-officer-febbo-phillip-g-covered-exercisetax-liability-6707108)
- 2026-09-04 23:54 UTC [SEC Form 4] [Global Chief Commercial Off Leite John covered exercise/tax liability with 3,961 shares, decreasing direct ownership by 3% to 128,344 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/global-chief-commercial-off-leite-john-covered-exercisetax-liability-with-6707107)
- 2026-09-03 20:48 UTC [SEC Form 4] [Director Bhanji Muna sold $80,096 worth of shares (1,864 units at $42.97) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,718 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bhanji-muna-sold-80096-worth-of-shares-1864-units-6705507)
- 2026-09-01 20:05 UTC [Conference Announcement] [Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference](https://www.quantisnow.com/insight/veracyte-to-participate-in-the-morgan-stanley-24th-annual-global-6701289)
- 2026-07-31 20:11 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Veracyte Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-veracyte-inc-6657860)
- 2026-07-30 20:18 UTC [SEC Form 8-K] [Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/veracyte-inc-filed-sec-form-8-k-results-of-operations-and-6656285)
- 2026-07-30 20:05 UTC [Earnings Date] [Veracyte Announces Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/veracyte-announces-second-quarter-2026-financial-results-6655973)
- 2026-07-28 20:05 UTC [Conference Announcement] [Veracyte to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/veracyte-to-participate-in-upcoming-investor-conferences-6651375)
- 2026-07-15 12:52 UTC [Analyst Coverage Initiated] [Piper Sandler initiated coverage on Veracyte with a new price target](https://www.quantisnow.com/insight/piper-sandler-initiated-coverage-on-veracyte-with-a-new-price-6637809)
- 2026-07-09 20:05 UTC [Earnings Date] [Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026](https://www.quantisnow.com/insight/veracyte-to-release-second-quarter-2026-financial-results-on-july-6632963)
- 2026-06-22 20:30 UTC [SEC Form 4] [Director Eastham Karin sold $197,234 worth of shares (3,729 units at $52.89) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 15,097 units (SEC Form 4)](https://www.quantisnow.com/insight/director-eastham-karin-sold-197234-worth-of-shares-3729-units-6610927)
- 2026-06-18 20:23 UTC [SEC Form 144] [SEC Form 144 filed by Veracyte Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-veracyte-inc-6608906)
- 2026-06-15 20:56 UTC [SEC Form 4] [Director Eastham Karin was granted 5,272 shares, increasing direct ownership by 39% to 18,826 units (SEC Form 4)](https://www.quantisnow.com/insight/director-eastham-karin-was-granted-5272-shares-increasing-direct-ownership-6603036)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VCYT
- Earnings history: https://www.quantisnow.com/earnings/VCYT
- Dividend history: https://www.quantisnow.com/dividends/VCYT
- Insider transactions: https://www.quantisnow.com/insiders/VCYT
- Options chain: https://www.quantisnow.com/options/VCYT
- SEC 8-K filings only: https://www.quantisnow.com/company/VCYT/8-k
- RSS and alerts for VCYT: https://www.quantisnow.com/docs/rss-feeds.md